The global hyaluronic acid-based dermal fillers market size was estimated to be USD 4.82 billion in 2023 and is expected to reach at USD 12.39 billion by 2034 with a CAGR of 8.96% during the forecast period 2024-2034. Increasing demand for non-invasive aesthetic procedures, surge in awareness regarding the application of Hyaluronic Acid (HA) in beauty segment, growing investment in R&D for novel advanced innovations in dermal products, rising trend of aesthetic procedures among men, increasing the demand for facial dermal fillers, surge in preference for non-invasive procedure, growing awareness regarding the importance of aesthetic appearance, rising technological advancements, increasing launch of new products, and surge in regulatory authority approvals of novel products are some of the key factors boosting the market growth.
Surge in regulatory authority approvals of novel products is predicted to boost the market growth during the forecast period. Dermal fillers are a category of soft tissue fillers that are administered into the skin to rejuvenate and create a smoother appearance. They are commonly employed to reduce the appearance of wrinkles and other signs of aging on the skin. These fillers are a popular choice for augmenting the cheeks and lips, improving facial contours, and filling in facial creases and lines. They are also used for treating shallow and fine wrinkles with products like Belotero and Restylane Silk, which aid in preventing skin aging. Consequently, major industry players are committed to advancing solutions in the hyaluronic acid market. For instance, in January 2022, RHA Redensity, an innovative dermal filler designed to reduce skin wrinkles, has obtained approval from the U.S. FDA. This gel implant is made from sodium hyaluronic acid and is injected into specific facial areas to effectively smooth out lines and wrinkles.
By product, single-phase products was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the wide range of applications of technology in skin & facial procedures, reduced side effects, rising advancement of technology, which has led to the creation of new types of fillers, growing use of Hylacross technology in the manufacturing of single-phase fillers like Juvederm Ultra ensures product durability & potential advantages, and increasing regulatory approvals. For instance, in June 2023, Galderma has revealed that the U.S. Food and Drug Administration (FDA) has granted approval for Restylane Eyelight, intended for the treatment of undereye hollows, commonly referred to as dark shadows, in adults aged 21 and older. Restylane Eyelight, a hyaluronic acid (HA) dermal filler designed for the undereye area, is the first and only product in the United States to incorporate NASHA Technology, addressing volume loss under the eyes and delivering natural-looking results for patients. Additionally, duplex products is predicted to grow at fastest CAGR during the forecast period. The Cohesive Intensified Matrix technique is utilized to create duplex hyaluronic acid products. The increased durability of these duplex products has led to their use in the treatment of glabellar lines and nasolabial folds. A study on Belotero HA filler indicates that CPM technological solutions provide a soft and smooth injection process, enabling the integration of homogeneous tissue.
By application, wrinkle correction was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the increasing awareness among customers & their desire for a more youthful appearance, rising technological advancements in hyaluronic acid-based treatments, the proliferation of new products & procedures for anti-wrinkle treatments, and growing approval of advanced products by regulatory bodies. For instance, in February 2022, Allergan Aesthetics, a subsidiary of AbbVie, Inc., has disclosed that the FDA has granted approval for JUVEDERM VOLBELLA XC for use in adults aged 21 and above to enhance infraorbital hollows. This approval reflects the company's commitment to expanding its treatment offerings in order to meet the requirements of patients effectively. Additionally, lip augmentation is predicted to grow at fastest CAGR during the forecast period owing to a rising level of involvement & contributions from significant market players, increasing adoption of cosmetic procedure aimed at increasing the volume of the lips by using fillers, and growing demand for Hyaluronic Acid-based Dermal Filler injections for enhancing & defining the lips.
By end-user, specialty & dermatology clinics was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the growing number of dermatology clinics, increasing use of HA-based fillers in procedures, rising prevalence of aesthetic issues such as wrinkles, acne, & scarring, and surge in approval of new products by regulatory authorities. For instance, in May 2023, Allergan Aesthetics, a subsidiary of AbbVie, Inc., has declared that the U.S. FDA has granted approval for SKINVIVE by JUVÉDERM, intended for enhancing the smoothness of cheeks in adults aged 21 and above. SKINVIVE by JUVÉDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the United States, with results lasting up to six months with optimal treatment. Additionally, hospitals & clinics is predicted to grow at fastest CAGR during the forecast period owing to the expansion of cosmetic procedures within hospital settings and the rising number of hospitals across the globe.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of non-invasive cosmetic procedures performed, rising investment in research & development activities, growing healthcare infrastructure, and increasing focus on expansion by leading market players. For instance, in May 2023, Evolus has revealed its expansion into the U.S. dermal filler market with Evolysse, a first-generation cold technology hyaluronic acid (HA) product developed by Symatese. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing aging population, rising preference for anti-aging procedures involving hyaluronic acid-based dermal fillers, increasing awareness of non-invasive methods for aesthetic treatments, and surge in launch of new products. For instance, in August 2022, Allergan Healthcare India Private Limited has introduced Juvéderm VOLUX in India as part of its Business Unit, Allergan Aesthetics. The company obtained all the required approvals from the Central Drugs Standards Control Organization (CDSCO) before launching this product in India. Juvéderm VOLUX is an injectable implant designed to restore and enhance facial volume and comprises 25 mg of Hyaluronic acid and 3 mg of Lidocaine hydrochloride.
Surge in regulatory authority approvals of novel products is predicted to boost the market growth during the forecast period. Dermal fillers are a category of soft tissue fillers that are administered into the skin to rejuvenate and create a smoother appearance. They are commonly employed to reduce the appearance of wrinkles and other signs of aging on the skin. These fillers are a popular choice for augmenting the cheeks and lips, improving facial contours, and filling in facial creases and lines. They are also used for treating shallow and fine wrinkles with products like Belotero and Restylane Silk, which aid in preventing skin aging. Consequently, major industry players are committed to advancing solutions in the hyaluronic acid market. For instance, in January 2022, RHA Redensity, an innovative dermal filler designed to reduce skin wrinkles, has obtained approval from the U.S. FDA. This gel implant is made from sodium hyaluronic acid and is injected into specific facial areas to effectively smooth out lines and wrinkles.
By product, single-phase products was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the wide range of applications of technology in skin & facial procedures, reduced side effects, rising advancement of technology, which has led to the creation of new types of fillers, growing use of Hylacross technology in the manufacturing of single-phase fillers like Juvederm Ultra ensures product durability & potential advantages, and increasing regulatory approvals. For instance, in June 2023, Galderma has revealed that the U.S. Food and Drug Administration (FDA) has granted approval for Restylane Eyelight, intended for the treatment of undereye hollows, commonly referred to as dark shadows, in adults aged 21 and older. Restylane Eyelight, a hyaluronic acid (HA) dermal filler designed for the undereye area, is the first and only product in the United States to incorporate NASHA Technology, addressing volume loss under the eyes and delivering natural-looking results for patients. Additionally, duplex products is predicted to grow at fastest CAGR during the forecast period. The Cohesive Intensified Matrix technique is utilized to create duplex hyaluronic acid products. The increased durability of these duplex products has led to their use in the treatment of glabellar lines and nasolabial folds. A study on Belotero HA filler indicates that CPM technological solutions provide a soft and smooth injection process, enabling the integration of homogeneous tissue.
By application, wrinkle correction was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the increasing awareness among customers & their desire for a more youthful appearance, rising technological advancements in hyaluronic acid-based treatments, the proliferation of new products & procedures for anti-wrinkle treatments, and growing approval of advanced products by regulatory bodies. For instance, in February 2022, Allergan Aesthetics, a subsidiary of AbbVie, Inc., has disclosed that the FDA has granted approval for JUVEDERM VOLBELLA XC for use in adults aged 21 and above to enhance infraorbital hollows. This approval reflects the company's commitment to expanding its treatment offerings in order to meet the requirements of patients effectively. Additionally, lip augmentation is predicted to grow at fastest CAGR during the forecast period owing to a rising level of involvement & contributions from significant market players, increasing adoption of cosmetic procedure aimed at increasing the volume of the lips by using fillers, and growing demand for Hyaluronic Acid-based Dermal Filler injections for enhancing & defining the lips.
By end-user, specialty & dermatology clinics was the highest revenue-grossing segment in the global hyaluronic acid-based dermal fillers market in 2023 owing to the growing number of dermatology clinics, increasing use of HA-based fillers in procedures, rising prevalence of aesthetic issues such as wrinkles, acne, & scarring, and surge in approval of new products by regulatory authorities. For instance, in May 2023, Allergan Aesthetics, a subsidiary of AbbVie, Inc., has declared that the U.S. FDA has granted approval for SKINVIVE by JUVÉDERM, intended for enhancing the smoothness of cheeks in adults aged 21 and above. SKINVIVE by JUVÉDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the United States, with results lasting up to six months with optimal treatment. Additionally, hospitals & clinics is predicted to grow at fastest CAGR during the forecast period owing to the expansion of cosmetic procedures within hospital settings and the rising number of hospitals across the globe.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of non-invasive cosmetic procedures performed, rising investment in research & development activities, growing healthcare infrastructure, and increasing focus on expansion by leading market players. For instance, in May 2023, Evolus has revealed its expansion into the U.S. dermal filler market with Evolysse, a first-generation cold technology hyaluronic acid (HA) product developed by Symatese. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing aging population, rising preference for anti-aging procedures involving hyaluronic acid-based dermal fillers, increasing awareness of non-invasive methods for aesthetic treatments, and surge in launch of new products. For instance, in August 2022, Allergan Healthcare India Private Limited has introduced Juvéderm VOLUX in India as part of its Business Unit, Allergan Aesthetics. The company obtained all the required approvals from the Central Drugs Standards Control Organization (CDSCO) before launching this product in India. Juvéderm VOLUX is an injectable implant designed to restore and enhance facial volume and comprises 25 mg of Hyaluronic acid and 3 mg of Lidocaine hydrochloride.
Segmentation: Hyaluronic Acid-based Dermal Fillers Market Report 2023 - 2034
Hyaluronic Acid-based Dermal Fillers Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Duplex Products
- Single Phase Products
Hyaluronic Acid-based Dermal Fillers Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Lip Augmentation
- Wrinkle Correction
- Rhinoplasty
- Others
Hyaluronic Acid-based Dermal Fillers Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals & Clinics
- Specialty & Dermatology Clinics
- Others
Hyaluronic Acid-based Dermal Fillers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hyaluronic Acid-based Dermal Fillers Market: Product Estimates & Trend Analysis
8. Hyaluronic Acid-based Dermal Fillers Market: Application Estimates & Trend Analysis
9. Hyaluronic Acid-based Dermal Fillers Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Hyaluronic Acid-based Dermal Fillers Market
12. Europe Global Hyaluronic Acid-based Dermal Fillers Market
13. Asia Pacific Global Hyaluronic Acid-based Dermal Fillers Market
14. Latin America Global Hyaluronic Acid-based Dermal Fillers Market
15. MEA Global Hyaluronic Acid-based Dermal Fillers Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Anika Therapeutics Inc.
- Bohus Biotech AB
- Allergan
- Merz Pharmaceuticals
- Galderma Laboratories
- Bio plus Co. Ltd.
- LG Life Sciences Ltd (LG Chem)
- Sculpt Luxury
- Dermal Fillers Ltd
- Vivacy
- Bioxis Pharmaceutical
- Genzyme Corporation
- Sinclair Pharma Laboratories
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.82 Billion |
| Forecasted Market Value ( USD | $ 12.39 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
